Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
| Revenue (TTM) | $11.58B |
| Gross Profit (TTM) | $7.72B |
| EBITDA | $4.47B |
| Operating Margin | 33.30% |
| Return on Equity | 17.90% |
| Return on Assets | 11.80% |
| Revenue/Share (TTM) | $32.78 |
| Book Value | $46.12 |
| Price-to-Book | 10.35 |
| Price-to-Sales (TTM) | 13.82 |
| EV/Revenue | 13.95 |
| EV/EBITDA | 35.32 |
| Quarterly Earnings Growth (YoY) | -23.60% |
| Quarterly Revenue Growth (YoY) | 21.70% |
| Shares Outstanding | $353.28M |
| Float | $344.60M |
| % Insiders | 0.52% |
| % Institutions | 91.24% |
Volatility is currently expanding
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Intuitive Surgical's ISRG third-quarter 2026 system placements reflect continued demand for robotic-assisted surgery, although the increase does not clearly signal a broad-based acceleration in hospital capital spending. Da Vinci placements rose 28% year over year to 546 systems from 427, while net placements — which expand the installed base — grew 40%.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
SUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the appointment of Aaron Martin, President of Insurance at Humana, to its board of directors, effective January 1, 2027.
Intuitive Surgical is a leader in the surgical robotics space, with a huge installed base of its da Vinci robots. The company's biggest source of revenue, by a wide margin, is the sale of parts and services.
Intuitive Surgical's surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific despite its valuation premium.
Intuitive Surgical's ISRG third-quarter 2026 revenues increased 22% year over year to just over $3 billion, outpacing 15% growth in total da Vinci and Ion procedures. Sales growth substantially exceeding procedure growth underscores the company's ability to capitalize on its expanding installed base, increased system placements and growing adoption of newer technologies.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Intuitive Surgical (ISRG) possesses solid growth attributes, which could help it handily outperform the market.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ISRG and any ticker you trade — then tracks every position and per-strategy win rate.
